IHZD Institutes Unveiling Sale to Affidea Group
Deal News | Feb 10, 2025 | Legal Community Swiss
Niederer Kraft Frey (NKF) has advised the shareholders of the Swiss medical research institute IHZD on its acquisition by Affidea Group. IHZD, which is renowned for its expertise in histopathology, molecular pathology, and cytology diagnostics, operates two laboratories located in Aarau and Zurich. Affidea Group, one of Europe's largest providers of diagnostic imaging and cancer treatment services, has finalized the acquisition, seeking to bolster their oncological treatment offerings. The acquisition enables Affidea to further harmonize comprehensive oncological services encompassing prevention, early detection, genetic testing, diagnosis, personalized treatment, and aftercare. The legal team from NKF, headed by Corporate/M&A partner Thomas Brnnimann, included associates from various specialty areas such as corporate, employment, and tax law.
Sectors
- Healthcare
- Legal Services
- Private Equity & Mergers and Acquisitions
Geography
- Switzerland – Switzerland is relevant as the location where IHZD operates its medical research institutes in Aarau and Zurich.
- Europe – Europe is significant here as Affidea Group is described as one of Europe's largest providers of diagnostic imaging and cancer treatment, showing their geographic reach and focus.
Industry
- Healthcare – The healthcare industry involves the provision of medical services, manufacturing of medical equipment, and facilitation of diagnostics services, which is directly relevant given IHZD's laboratory operations and Affidea's healthcare services.
- Legal Services – The article involves NKF’s advisory services on a corporate transaction, highlighting the involvement of legal advisory services.
- Private Equity & Mergers and Acquisitions – The acquisition of IHZD by Affidea falls under the transactions typically seen in the M&A sector, involving the integration of healthcare services and expansion of the business model within this industry.
Financials
- – No specific financial figures are provided in the article regarding the transaction.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| IHZD Institut für histologische und zytologische Diagnostik | Target | Company | A Swiss medical research institute specialized in histopathology, molecular pathology, and cytology diagnostics. |
| Affidea Group | Buyer | Company | A major European provider of diagnostic imaging, ambulatory care, and cancer treatment services that acquired IHZD to enhance its oncology treatment offerings. |
| Niederer Kraft Frey (NKF) | Legal Advisor | Company | A law firm advising the shareholders of IHZD in the sale transaction to Affidea Group. |
| Thomas Brnnimann | Corporate/M&A Partner | Person | Lead partner at NKF responsible for overseeing the IHZD sale transaction. |